Use este identificador para citar ou linkar para este item:
https://www.arca.fiocruz.br/handle/icict/9727
MYCOBACTERIAL ANTIGEN DRIVEN ACTIVATION OF CD14++CD162 MONOCYTES IS A PREDICTOR OF TUBERCULOSIS-ASSOCIATED IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME
Autor(es)
Andrade, Bruno de Bezerril
Singh, Amrit
Narendran, Gopalan
Schechter, Melissa E.
Nayak, Kaustuv
Subramanian, Sudha
Anbalagan, Selvaraj
Jensen, Stig M. R.
Porter, Brian O.
Antonelli, Lis Ribeiro do Valle
Wilkinson, Katalin A.
Wilkinson, Robert J.
Meintjes, Graeme
Plas, Helen van der
Follmann, Dean
Barber, Daniel L.
Swaminathan, Soumya
Sher, Alan
Sereti, Irini
Singh, Amrit
Narendran, Gopalan
Schechter, Melissa E.
Nayak, Kaustuv
Subramanian, Sudha
Anbalagan, Selvaraj
Jensen, Stig M. R.
Porter, Brian O.
Antonelli, Lis Ribeiro do Valle
Wilkinson, Katalin A.
Wilkinson, Robert J.
Meintjes, Graeme
Plas, Helen van der
Follmann, Dean
Barber, Daniel L.
Swaminathan, Soumya
Sher, Alan
Sereti, Irini
Afiliação
National Institutes of Health. National Institute of Allergy and Infectious Diseases. Laboratory of Parasitic Diseases. Immunobiology Section. Bethesda, MD, United States of America
National Institutes of Health. National Institute of Allergy and Infectious Diseases.Laboratory of Immunoregulation. Clinical and Molecular Retrovirology Section. Bethesda, MD, United States of America
National Institute for Research in Tuberculosis. Chennai, India
National Institutes of Health. National Institute of Allergy and Infectious Diseases.Laboratory of Immunoregulation. Clinical and Molecular Retrovirology Section. Bethesda, MD, United States of America
National Institute for Research in Tuberculosis. Chennai, India
National Institute for Research in Tuberculosis. Chennai, India
National Institute for Research in Tuberculosis. Chennai, India
National Institutes of Health. National Institute of Allergy and Infectious Diseases.Laboratory of Immunoregulation. Clinical and Molecular Retrovirology Section. Bethesda, MD, United States of America
National Institutes of Health. National Institute of Allergy and Infectious Diseases.Laboratory of Immunoregulation. Clinical and Molecular Retrovirology Section. Bethesda, MD, United States of America
Laboratório de Imunopatologia, Centro de Pesquisas René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Minas Gerais, Brazil
University of Cape Town. Institute of Infectious Disease and Molecular Medicine, and Department of Medicine. Clinical Infectious Diseases Research Initiative. Cape Town, South Africa
University of Cape Town. Institute of Infectious Disease and Molecular Medicine, and Department of Medicine. Clinical Infectious Diseases Research Initiative. Cape Town, South Africa/Imperial College London. Department of Medicine. London, United Kingdom/MRC National Institute for Medical Research. London, United Kingdom
University of Cape Town. Institute of Infectious Disease and Molecular Medicine, and Department of Medicine. Clinical Infectious Diseases Research Initiative. Cape Town, South Africa/Imperial College London. Department of Medicine. London, United Kingdom
University of Cape Town. Institute of Infectious Disease and Molecular Medicine, and Department of Medicine. Clinical Infectious Diseases Research Initiative. Cape Town, South Africa
National Institutes of Health. National Institute of Allergy and Infectious Diseases. Biostatistics Research Branch. Bethesda, MD, United States of America
National Institutes of Health. National Institute of Allergy and Infectious Diseases. T-Lymphocyte Biology Unit, Laboratory of Parasitic Diseases. Bethesda, MD, United States of America
National Institute for Research in Tuberculosis. Chennai, India
National Institutes of Health. National Institute of Allergy and Infectious Diseases. Laboratory of Parasitic Diseases. Immunobiology Section. Bethesda, MD, United States of America
National Institutes of Health. National Institute of Allergy and Infectious Diseases.Laboratory of Immunoregulation. Clinical and Molecular Retrovirology Section. Bethesda, MD, United States of America
National Institutes of Health. National Institute of Allergy and Infectious Diseases.Laboratory of Immunoregulation. Clinical and Molecular Retrovirology Section. Bethesda, MD, United States of America
National Institute for Research in Tuberculosis. Chennai, India
National Institutes of Health. National Institute of Allergy and Infectious Diseases.Laboratory of Immunoregulation. Clinical and Molecular Retrovirology Section. Bethesda, MD, United States of America
National Institute for Research in Tuberculosis. Chennai, India
National Institute for Research in Tuberculosis. Chennai, India
National Institute for Research in Tuberculosis. Chennai, India
National Institutes of Health. National Institute of Allergy and Infectious Diseases.Laboratory of Immunoregulation. Clinical and Molecular Retrovirology Section. Bethesda, MD, United States of America
National Institutes of Health. National Institute of Allergy and Infectious Diseases.Laboratory of Immunoregulation. Clinical and Molecular Retrovirology Section. Bethesda, MD, United States of America
Laboratório de Imunopatologia, Centro de Pesquisas René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Minas Gerais, Brazil
University of Cape Town. Institute of Infectious Disease and Molecular Medicine, and Department of Medicine. Clinical Infectious Diseases Research Initiative. Cape Town, South Africa
University of Cape Town. Institute of Infectious Disease and Molecular Medicine, and Department of Medicine. Clinical Infectious Diseases Research Initiative. Cape Town, South Africa/Imperial College London. Department of Medicine. London, United Kingdom/MRC National Institute for Medical Research. London, United Kingdom
University of Cape Town. Institute of Infectious Disease and Molecular Medicine, and Department of Medicine. Clinical Infectious Diseases Research Initiative. Cape Town, South Africa/Imperial College London. Department of Medicine. London, United Kingdom
University of Cape Town. Institute of Infectious Disease and Molecular Medicine, and Department of Medicine. Clinical Infectious Diseases Research Initiative. Cape Town, South Africa
National Institutes of Health. National Institute of Allergy and Infectious Diseases. Biostatistics Research Branch. Bethesda, MD, United States of America
National Institutes of Health. National Institute of Allergy and Infectious Diseases. T-Lymphocyte Biology Unit, Laboratory of Parasitic Diseases. Bethesda, MD, United States of America
National Institute for Research in Tuberculosis. Chennai, India
National Institutes of Health. National Institute of Allergy and Infectious Diseases. Laboratory of Parasitic Diseases. Immunobiology Section. Bethesda, MD, United States of America
National Institutes of Health. National Institute of Allergy and Infectious Diseases.Laboratory of Immunoregulation. Clinical and Molecular Retrovirology Section. Bethesda, MD, United States of America
Resumo em Inglês
Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) is an aberrant inflammatory response occurring in a subset of TB-HIV co-infected patients initiating anti-retroviral therapy (ART). Here, we examined monocyte activation by prospectively quantitating pro-inflammatory plasma markers and monocyte subsets in TB-HIV co-infected patients from a South Indian cohort at baseline and following ART initiation at the time of IRIS, or at equivalent time points in non-IRIS controls. Pro-inflammatory biomarkers of innate and myeloid cell activation were increased in plasma of IRIS patients pre-ART and at the time of IRIS; this association was confirmed in a second cohort in South Africa. Increased expression of these markers correlated with elevated antigen load as measured by higher sputum culture grade and shorter duration of anti-TB therapy. Phenotypic analysis revealed the frequency of CD14++CD16− monocytes was an independent predictor of TB-IRIS, and was closely associated with plasma levels of CRP, TNF, IL-6 and tissue factor during IRIS. In addition, production of inflammatory cytokines by monocytes was higher in IRIS patients compared to controls pre-ART. These data point to a major role of mycobacterial antigen load and myeloid cell hyperactivation in the pathogenesis of TB-IRIS, and implicate monocytes and monocyte-derived cytokines as potential targets for TB-IRIS prevention or treatment.
Compartilhar